BioSpace News Archive

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has completed enrollment of the last patient in the study.

Micron Solutions, Inc. (OTCQB: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining and injection molding, announced results for its third quarter ended September 30, 2020. In the third quarter of 2020, the Company reported $5,636,000 in revenue, as compared to $4,331,000 in the th

Spiration Valve System Has Been Used to Treat More Than 500 Patients with Severe Emphysema - Their Stories Are an Inspiration to Others

Researchers from The Feinstein Institutes for Medical Research and two other institutions have been awarded a $52 million, five-year grant from the National Institute of Mental Health to lead an international study to understand the trajectory toward schizophrenia in high-risk youth.

Seal Rock Therapeutics, Inc., a late-preclinical stage biotechnology company developing first-in-class and best-in-class treatments for severe liver diseases with limited or no available therapies, today announced the presentation of data demonstrating comparative efficacy and pharmacokinetic findings on SRT-015, a second-generation,

A partnership between Susan G. Komen®, the Inflammatory Breast Cancer (IBC) Research Foundation and the Milburn Foundation® has raised nearly $1 million for more research into inflammatory breast cancer – an aggressive subtype of breast cancer that is challenging to diagnose and treat – and other important programs.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its continued partnership with the International Genetically Engineered Machine (iGEM) Foundation.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the third quarter ended September 30, 2020

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of the Twist Comprehensive Viral Research Panel, a next-generation sequencing (NGS) panel that includes more than 3,000 viral genomes to enable identification of new and divergent viral species in a single sample.